← All candidates
Five insider buys in the last year — $99.7K in all.
30 filings on record.
CUECue Biopharma, Inc.
NasdaqCM · Healthcare · $229.85M
$31.64
+3.57% · Sep 15
Five insider buys in the last year — $99.7K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 5 buys● 11 sells◆ 7 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CUE ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$229.85M
Float
6.8M
94% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
6.1
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Sarraf Pasha
Bought $27.6K on Dec 30 — 86,947 sh @ $0.3174, held direct, 52% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
24 more transactions on Pro →Context
Wall St
$115.00 avg target
+263.5% vs today · 1 analyst
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$1.08 act
Q4 '25$0.30 act+$3.00
Q3 '25−$2.10 act+$0.45
Q2 '25−$2.70 act+$1.20
Coverage
Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEOInsider Monkey · 04-20Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue EstimatesZacks · 11-12Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue EstimatesZacks · 08-123 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider OwnershipSimply Wall St. · 07-24
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice